Welcome to our dedicated page for LIGAND PHARMACEUTICALS SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIGAND PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIGAND PHARMACEUTICALS's regulatory disclosures and financial reporting.
LGND reporting person John Kozarich disclosed recent sales of Common Stock under Rule 144 procedures. The filing lists a planned Stock Option Exercise for 1,575 shares on 05/13/2026 through Morgan Stanley Smith Barney LLC as issuer-directed cash settlement. The record also lists four recent dispositions: 459, 467, 467, and 467 shares on 05/12/2026, 05/01/2026, 04/01/2026, and 03/02/2026 respectively, with gross proceeds shown in the filing.
John Kozarich submitted a Form 144 proposing the sale of 459 shares of Common Stock of the issuer on 05/12/2026.
The filing lists the sale method as a Stock Option Exercise with cash proceeds and identifies Morgan Stanley Smith Barney LLC as the broker. The excerpt also shows three prior dispositions by John Kozarich of 467 shares each on 05/01/2026, 04/01/2026, and 03/02/2026 with the reported gross amounts $111,519.60, $94,440.09, and $93,632.37, respectively.
Ligand Pharmaceuticals reported Q1 2026 revenues and income of $51.7 million, up from $45.3 million in Q1 2025, driven mainly by higher royalties. Royalties rose to $43.0 million from $27.5 million, including strong contributions from Filspari, Kyprolis and Qarziba.
The company generated operating income of $17.4 million versus a prior-year operating loss, but recorded a non-operating loss of $41.6 million largely from a $49.2 million fair value decline in Pelthos-related investments. Net loss narrowed to $13.3 million, or $0.67 per share, compared with a $42.5 million loss a year earlier.
Ligand ended March 31, 2026 with cash and cash equivalents of $115.1 million and short‑term investments of $664.3 million. It has $460.0 million of 0.75% convertible senior notes due 2030 outstanding and reported operating cash flow of $48.7 million for the quarter.
Ligand Pharmaceuticals reported first quarter 2026 results showing strong royalty-driven growth but a GAAP loss due to investment marks. Total revenues and income were $51.7 million, up 14% from $45.3 million a year earlier, as royalty revenue rose 56% to $43.0 million.
GAAP net loss narrowed to $13.3 million, or $0.67 per share, from a $42.5 million loss, mainly because 2025 included large one-time R&D charges. Adjusted net income increased to $34.6 million, or $1.63 per diluted share. Ligand reaffirmed 2026 guidance, including expected royalty revenue of $225–$250 million and total revenue of $270–$310 million, reflecting an anticipated partial-year contribution from the pending XOMA Royalty acquisition.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported a pre-planned option exercise and share sale. On May 1, 2026, he exercised employee stock options for 5,000 shares of common stock at $52.27 per share and sold 5,000 shares of common stock in open-market transactions at weighted-average prices ranging from about $227 to $234 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 24, 2025, indicating they were scheduled in advance rather than timed discretionarily.
LGND Rule 144 notice reporting proposed sales of Common shares. The filing lists 467 shares referenced repeatedly, an issuer listing at Nasdaq, and three recent sale entries by John Kozarich dated 02/02/2026, 03/02/2026, and 04/01/2026 with numeric values shown beside each entry.
Vanguard Portfolio Management reports beneficial ownership of 1,109,154 shares of Ligand Pharmaceuticals Inc. common stock, representing 5.56% of the class. The filing (Schedule 13G) shows sole voting power of 8,887 shares and sole dispositive power of 1,109,154 shares. The disclosure is signed by Ashley Grim on 05/01/2026 and lists CUSIP 53220K504.
Ligand Pharmaceuticals Inc ownership filing: Vanguard Capital Management reported beneficial ownership of 997,637 shares of Common Stock, representing 5% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 997,637 shares and sole voting power for 149,548 shares.
Ligand Pharmaceuticals agreed to acquire XOMA Royalty Corporation in an all-cash deal valuing XOMA Royalty at approximately $739 million, paying $39.00 per share plus one contingent value right (CVR) per share tied to 75% of certain Janssen litigation net proceeds.
The transaction will add seven commercial products and more than 100 development-stage royalty assets, expanding Ligand’s portfolio to over 200 assets and strengthening its position as a biopharma royalty aggregator. XOMA’s preferred stock is expected to be converted or redeemed, and XOMA stockholders will receive the CVRs in addition to cash.
Ligand raised its 2026 guidance, now targeting total revenue of $270–$310 million and adjusted EPS of $8.50–$9.50, with royalties of $225–$250 million, and expects the deal to add about $1.50 per share to adjusted EPS in 2027. Closing is expected in the third quarter of 2026, subject to XOMA stockholder and regulatory approvals and other customary conditions.